Peripheral neuropathies caused by mutations in the myelin protein zero

Related Experiment Video

Updated: Aug 13, 2026

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments
07:30

A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments

Published on: November 9, 2017

Michael E Shy1

  • 1Wayne State University, Department of Neurology, 421 Ea Canfield, Elliman Bldg 3206, Detroit, MI 48201, USA. m.shy@wayne.edu

Journal of the Neurological Sciences
|January 18, 2006
PubMed

Insights

Charcot-Marie-Tooth type 1B (CMT1B) results from mutations in the myelin protein zero (MPZ) gene. Understanding MPZ

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • Charcot-Marie-Tooth disease type 1B (CMT1B) is a peripheral nervous system (PNS) disorder.
  • It is caused by mutations in the myelin protein zero (MPZ) gene, encoding a key adhesion molecule in PNS myelin.
  • MPZ mutations disrupt myelin compaction and axo-glial interactions, leading to neuropathy.

Purpose of the Study:

  • To elucidate the molecular pathways underlying early and late-onset CMT1B.
  • To understand how MPZ mutations lead to distinct clinical presentations.
  • To identify potential therapeutic targets for CMT1B.

Main Methods:

  • Analysis of MPZ structure and function within the immunoglobulin supergene family.
  • Investigation of developmental myelination processes affected by MPZ mutations.
  • Study of axo-glial interactions disrupted in adult-onset CMT1B.

Main Results:

  • MPZ mutations disrupt PNS myelin development or maintenance.
  • Disruption of myelination leads to early-onset, severe neuropathies.
  • Disruption of axo-glial interactions causes late-onset neuropathies in adulthood.

Conclusions:

  • MPZ's role in myelin compaction and axo-glial signaling is critical for PNS health.
  • Distinct molecular pathways are affected in early vs. late-onset CMT1B.
  • Targeting these pathways may lead to effective CMT1B therapies.

More Related Videos

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons07:43

Modeling Charcot-Marie-Tooth Disease In Vitro by Transfecting Mouse Primary Motoneurons

Published on: January 7, 2019

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models08:57

Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models

Published on: May 17, 2024

Related Concept Videos

Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Nervous Tissue: Myelin01:25

Nervous Tissue: Myelin

The myelin sheath is a multilayered lipid and protein covering that insulates the axon of a neuron, enhancing the speed of nerve impulse conduction. Axons without this sheath are referred to as unmyelinated. Two types of neuroglia, Schwann cells in the peripheral nervous system (PNS) and oligodendrocytes in the central nervous system (CNS) are responsible for producing myelin sheaths.
Schwann cells begin to form myelin sheaths around axons during fetal development. They wrap around a small...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Peripheral Nervous System: Ganglia and Nerves01:24

Peripheral Nervous System: Ganglia and Nerves

The Peripheral Nervous System (PNS) is a crucial component of the body's neural network, extending beyond the central nervous system (CNS) to bridge the gap between the CNS and the external environment. It encompasses nerves, ganglia, and sensory receptors.
Nerves
The nerve is a bundle of axons that serves as the communication highway in the PNS. Each nerve is ensheathed in a protective layer of connective tissue called the epineurium. This outermost layer safeguards the nerve and supports the...
Mutations01:39

Mutations

Overview